BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 18975605)

  • 1. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmoteplase.
    Paciaroni M; Medeiros E; Bogousslavsky J
    Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
    Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
    Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with diffusion-perfusion mismatch on magnetic resonance imaging 48 hours or more after stroke symptom onset: clinical and imaging features.
    Perez A; Restrepo L; Kleinman JT; Barker P; Beauchamp N; Wityk RJ
    J Neuroimaging; 2006 Oct; 16(4):329-33. PubMed ID: 17032382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etiology of perfusion-diffusion magnetic resonance imaging mismatch patterns.
    Restrepo L; Jacobs MA; Barker PB; Beauchamp NJ; Skolasky RL; Keswani SC; Wityk RJ
    J Neuroimaging; 2005 Jul; 15(3):254-60. PubMed ID: 15951408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemic diffusion lesion reversal is uncommon and rarely alters perfusion-diffusion mismatch.
    Chemmanam T; Campbell BC; Christensen S; Nagakane Y; Desmond PM; Bladin CF; Parsons MW; Levi CR; Barber PA; Donnan GA; Davis SM;
    Neurology; 2010 Sep; 75(12):1040-7. PubMed ID: 20720188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
    Derex L; Nighoghossian N; Hermier M; Adeleine P; Berthezène Y; Philippeau F; Honnorat J; Froment JC; Trouillas P
    J Neurol Sci; 2004 Oct; 225(1-2):3-9. PubMed ID: 15465079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia.
    Schellinger PD; Fiebach JB; Jansen O; Ringleb PA; Mohr A; Steiner T; Heiland S; Schwab S; Pohlers O; Ryssel H; Orakcioglu B; Sartor K; Hacke W
    Ann Neurol; 2001 Apr; 49(4):460-9. PubMed ID: 11310623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.
    Warach S; Pettigrew LC; Dashe JF; Pullicino P; Lefkowitz DM; Sabounjian L; Harnett K; Schwiderski U; Gammans R
    Ann Neurol; 2000 Nov; 48(5):713-22. PubMed ID: 11079534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
    García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
    Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the ischemic penumbra using pH-weighted MRI.
    Sun PZ; Zhou J; Sun W; Huang J; van Zijl PC
    J Cereb Blood Flow Metab; 2007 Jun; 27(6):1129-36. PubMed ID: 17133226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of blood pressure variability after thrombolysis in acute stroke.
    Delgado-Mederos R; Ribo M; Rovira A; Rubiera M; Munuera J; Santamarina E; Delgado P; Maisterra O; Alvarez-Sabin J; Molina CA
    Neurology; 2008 Aug; 71(8):552-8. PubMed ID: 18550860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of magnetic resonance angiography-diffusion weighted imaging mismatch in hyperacute cerebral infarction.
    Deguchi I; Takeda H; Furuya D; Dembo T; Nagoya H; Kato Y; Ito Y; Fukuoka T; Maruyama H; Tanahashi N
    J Stroke Cerebrovasc Dis; 2012 Feb; 21(2):108-13. PubMed ID: 20851627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automatic prediction of infarct growth in acute ischemic stroke from MR apparent diffusion coefficient maps.
    Montiel NH; Rosso C; Chupin N; Deltour S; Bardinet E; Dormont D; Samson Y; Baillet S
    Acad Radiol; 2008 Jan; 15(1):77-83. PubMed ID: 18078910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk.
    Kumar S; Savitz S; Schlaug G; Caplan L; Selim M
    Neurology; 2006 Apr; 66(8):1153-8; discussion 1135. PubMed ID: 16636230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.